title: Pro: Antifibrinolytics Should Be Used in Routine Cardiac Cases Using Cardiopulmonary Bypass (Unless Contraindicated).
authors.affiliation: Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: apustav1@jhmi.edu.
authors.forename: Aliaksei
authors.initials: A
authors.lastname: Pustavoitau
authors.affiliation: Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
authors.forename: Nauder
authors.initials: N
authors.lastname: Faraday
mesh_terms: D015119:Aminocaproic Acid / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D014148:Tranexamic Acid / Q000627:therapeutic use
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid; D015119:Aminocaproic Acid
keywords: aminocaproic acid; antifibrinolytic agents; blood transfusion; cardiac surgical procedures; cardiopulmonary bypass; lysine analogs; tranexamic acid